However, therapeutic attempts to interfere with the mTOR/PI3K/AKT pathway using mTORC1 inhibitors (e.g., rapalogs) demonstrated low efficacy against myeloma because of induction of negative feedback circuits increasing mTORC2 activity (30, 31). Here, AKT1 is linked to plasma cell myeloma.